Clinical trials: Patients Undergoing Open Hernia Repair
Ventral Hernia
Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair
The purpose of this study is to determine whether Alvimopan (Entereg) in ventral hernia surgery patients is associated with accelerated gastrointestinal recovery and reduced length of hospital stay compared to placebo controls.
- Trial name
- NCT02379858
- Testing
- Alvimopan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical College of Wisconsin
Hernia
A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch
The objective of this study is to assess the recurrence rate following the use of PARIETEX™ Composite Ventral Patch in primary ventral hernia repair by open approach with intra-peritoneal positioning.
- Trial name
- Panacea (NCT01848184)
- Testing
- PARIETEX™ Composite Ventral Patch
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 126 people
- Sponsor
- Medtronic - MITG
Ventral Hernia
A Comparison of Fortiva and Strattice Tissue Matrices in Complex, Ventral Hernia Repair
The objective of this study is to compare the effectiveness of Fortiva Porcine Dermis versus Strattice Reconstructive Tissue Matrix for the underlay reinforcement of complex ventral hernia repair and assess post-operative…
- Trial name
- NCT02587403
- Testing
- Fortiva™ Porcine Dermis, Strattice™ Reconstructive Tissue Matrix
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- RTI Surgical
Postoperative Pain, Hernia
A Safety and Efficacy Study of SABER®-Bupivacaine for Pain Following Hernia Repair
This is a research study testing SABER-Bupivacaine (an experimental pain-relieving medication). SABER-Bupivacaine is designed to continuously deliver bupivacaine, a common local anesthetic, for a few days in order to treat local…
- Conditions
- Postoperative Pain, Hernia, Surgery
- Trial name
- NCT00974350
- Testing
- SABER-Bupivacaine
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 124 people
- Sponsor
- Durect